Cargando…

Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice

BACKGROUND: The most important limitations of morphine in pain therapy are its tolerance and dependence. In this study, we evaluated the protective effect of glucosamine against morphine-induced tolerance and dependence in mice. METHODS: Mice received twice daily morphine (20 mg/kg, s.c.) alone, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Basiri, Faezeh, Rad, Abolfazl, Mahdian, Davood, Molavi, Mehdi, Amin, Bahareh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380027/
https://www.ncbi.nlm.nih.gov/pubmed/30782159
http://dx.doi.org/10.1186/s12929-019-0513-1
_version_ 1783396236722700288
author Basiri, Faezeh
Rad, Abolfazl
Mahdian, Davood
Molavi, Mehdi
Amin, Bahareh
author_facet Basiri, Faezeh
Rad, Abolfazl
Mahdian, Davood
Molavi, Mehdi
Amin, Bahareh
author_sort Basiri, Faezeh
collection PubMed
description BACKGROUND: The most important limitations of morphine in pain therapy are its tolerance and dependence. In this study, we evaluated the protective effect of glucosamine against morphine-induced tolerance and dependence in mice. METHODS: Mice received twice daily morphine (20 mg/kg, s.c.) alone, or along with orally administered glucosamine (500, 1000 and 2000 mg/kg), for 9 continuous days. To assess antinociceptive effect of morphine, percentage of maximal possible effect (%MPE) of animals exposed to thermal stimulus was measured in the hot plate test, 30 min after morphine administration. Test was performed on days 1, 3, 5, 7 and 9. The effect of glucosamine on the naloxone (5 mg/kg, i.p.)-precipitated morphine withdrawal, was also evaluated. Changes in brain gene expression levels of induced nitric oxide synthase (iNOS), enzyme responsible for nitric oxide generation, as well as pro-inflammatory mediator, tumor necrosis alpha (TNF-α) were measured in morphine tolerated animals, as well as after withdrawal by real-time polymerase chain reaction (RT-PCR). Protein content of TNF-α was evaluated via ELISA assay. RESULTS: Tolerance to antinociceptive effect of morphine was developed after 7 days of morphine treatment. The concurrent administration of glucosamine (500, 1000 and 2000 mg/kg) with morphine, significantly inhibited tolerance development, on days 7 and 9. In addition, glucosamine ameliorated the naloxone-precipitated opioid withdrawal symptoms (tremor, jumping, teeth chattering, grooming). However, diarrhea was significantly improved only with the dose of 500 mg/kg. Increased mRNA expression of iNOS as well as TNF-α mRNA expression and protein, after both morphine tolerance and withdrawal, were considerably reduced by glucosamine (1000 mg/kg) in the morphine withdrawal animals. CONCLUSION: These data support the utility of glucosamine in attenuating both tolerance to nociceptive effects of morphine as well as withdrawal-induced behavioral profile. Anti-oxidant and anti-inflammatory effects are responsible, at least in part, for the protective effects of this drug.
format Online
Article
Text
id pubmed-6380027
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63800272019-02-28 Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice Basiri, Faezeh Rad, Abolfazl Mahdian, Davood Molavi, Mehdi Amin, Bahareh J Biomed Sci Research BACKGROUND: The most important limitations of morphine in pain therapy are its tolerance and dependence. In this study, we evaluated the protective effect of glucosamine against morphine-induced tolerance and dependence in mice. METHODS: Mice received twice daily morphine (20 mg/kg, s.c.) alone, or along with orally administered glucosamine (500, 1000 and 2000 mg/kg), for 9 continuous days. To assess antinociceptive effect of morphine, percentage of maximal possible effect (%MPE) of animals exposed to thermal stimulus was measured in the hot plate test, 30 min after morphine administration. Test was performed on days 1, 3, 5, 7 and 9. The effect of glucosamine on the naloxone (5 mg/kg, i.p.)-precipitated morphine withdrawal, was also evaluated. Changes in brain gene expression levels of induced nitric oxide synthase (iNOS), enzyme responsible for nitric oxide generation, as well as pro-inflammatory mediator, tumor necrosis alpha (TNF-α) were measured in morphine tolerated animals, as well as after withdrawal by real-time polymerase chain reaction (RT-PCR). Protein content of TNF-α was evaluated via ELISA assay. RESULTS: Tolerance to antinociceptive effect of morphine was developed after 7 days of morphine treatment. The concurrent administration of glucosamine (500, 1000 and 2000 mg/kg) with morphine, significantly inhibited tolerance development, on days 7 and 9. In addition, glucosamine ameliorated the naloxone-precipitated opioid withdrawal symptoms (tremor, jumping, teeth chattering, grooming). However, diarrhea was significantly improved only with the dose of 500 mg/kg. Increased mRNA expression of iNOS as well as TNF-α mRNA expression and protein, after both morphine tolerance and withdrawal, were considerably reduced by glucosamine (1000 mg/kg) in the morphine withdrawal animals. CONCLUSION: These data support the utility of glucosamine in attenuating both tolerance to nociceptive effects of morphine as well as withdrawal-induced behavioral profile. Anti-oxidant and anti-inflammatory effects are responsible, at least in part, for the protective effects of this drug. BioMed Central 2019-02-19 /pmc/articles/PMC6380027/ /pubmed/30782159 http://dx.doi.org/10.1186/s12929-019-0513-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Basiri, Faezeh
Rad, Abolfazl
Mahdian, Davood
Molavi, Mehdi
Amin, Bahareh
Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title_full Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title_fullStr Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title_full_unstemmed Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title_short Effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
title_sort effects of glucosamine against morphine-induced antinociceptive tolerance and dependence in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380027/
https://www.ncbi.nlm.nih.gov/pubmed/30782159
http://dx.doi.org/10.1186/s12929-019-0513-1
work_keys_str_mv AT basirifaezeh effectsofglucosamineagainstmorphineinducedantinociceptivetoleranceanddependenceinmice
AT radabolfazl effectsofglucosamineagainstmorphineinducedantinociceptivetoleranceanddependenceinmice
AT mahdiandavood effectsofglucosamineagainstmorphineinducedantinociceptivetoleranceanddependenceinmice
AT molavimehdi effectsofglucosamineagainstmorphineinducedantinociceptivetoleranceanddependenceinmice
AT aminbahareh effectsofglucosamineagainstmorphineinducedantinociceptivetoleranceanddependenceinmice